30 results about "Hematopoietic Tumor" patented technology

The present invention recognizes that diagnosis and prognosis of many conditions can depend on the enrichment of rare cells, especially tumor cells, from a complex fluid sample such as a blood sample. In particular, the present invention is directed to methods and compositions for detecting a non-hematopoietic cell, e.g., a non-hematopoietic tumor cell, in a blood sample via, inter alia, removing red blood cells (RBCs) from a blood sample using a non-centrifugation procedure, removing white blood cells (WBCs) from said blood sample to enrich a non-hematopoietic cell, if any, from said blood sample; and assessing the presence, absence and/or amount of said enriched non-hematopoietic cell.

The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.

The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for members of the immunoglobulin (Ig) and/or toll-like receptor superfamilies that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells.

The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same.

The invention relates to a kit for detecting an expression index of mRNA (messager Ribose Nucleic Acid) of a WT1 (Wilms Tumor 1) gene, and belongs to the field of biotechnology. The kit comprises detection primers, a fluorescent probe, a cDNA (complementary Deoxyribose Nucleic Acid) first strand synthesis reagent, a fluorescent quantitative PCR (Polymerase Chain Reaction) mixed solution, negative reference and positive reference, wherein the detection primers and the fluorescent probe comprise a WT1 gene primer, an internal reference gene ABL primer and a Taqman fluorescent probe. The WT1 gene is related with hematopoietic tumor incidence, is of over-expression in about 80% of patients with newly diagnosed acute myelocytic leukemia and acute lymphocytic leukemia, is recognized as a leukemia marker gene, and can serve as an independent minimal residue disease monitoring and prognosis prompting index. The level of the mRNA of the WT1 gene is detected by adopting a fluorescent quantitative PCR technology with higher sensitivity and specificity, and both the specificity and the sensitivity of a detection result are remarkably improved. The kit provides a brand-new quick, simple and convenient gene diagnosis technology for prognosing the acute myelocytic leukemia and the acute lymphocytic leukemia and confirming chemotherapy regimens.

Disclosed are methods for detecting adriamycin resistance in a test neoplastic cell from a non-hematological cancer. The methods include detecting a level of p16 expression in the test neoplastic cell of a given origin or cell type, and comparing the level of p16 expression detected in the test neoplastic cell to the level of p16 expression in a nonresistant neoplastic cell of the same origin or cell type, wherein the test neoplastic cell is adriamycin resistant if the level of p16 expression is greater than the level of p16 expression in the nonresistant neoplastic cell of the same origin or cell type. Also disclosed are therapeutic compositions comprising an agent that inhibits p16 and a pharmaceutically acceptable carrier.

A therapeutic and/or prophylactic agent for a hematopoietic tumor, which comprises a thiadiazoline derivative represented by the general formula (I), or a pharmaceutically acceptable salt thereof:

[Formula 1]

[wherein, n represents an integer of 1 to 3, R¹ represents a hydrogen atom, R² represents lower alkyl, or R¹ and R² are combined together to represent alkylene, R³ represents lower alkyl, R⁴ represents NHSO₂R⁶ (wherein R⁶ represents hydroxy or the like) or the like, and R⁵ represents aryl or the like] and the like are provided.

The present invention relates to a method for the diagnosis of low overall survival acute promyelocytic leukemia and/or of predicting and/or monitoring the response and/or the efficacy of a therapy for acute promyelocytic leukemia or to identify a subject to be treated with an inhibitor of HAT and/or an inhibitor of EZH2 by determining the acetylation or methylation status of specific relevant regions and relative kit and microarray. The invention also refers to histone acetyl transferase (HAT) inhibitor for use in the treatment of a solid or hematopoietic tumor.

In the present invention, a useful molecular target for a specific immunotherapy of hematologic malignancies was found, and a means capable of preventing and/or treating hematologic malignancies was provided. Specifically, provided were the followings: an agent for preventing and/or treating hematologic malignancies comprising as an active ingredient at least one peptide having an amino acid sequence selected from any one of SEQ ID NOs: 1 to 10 in the sequence listing; the agent for preventing and/or treating hematologic malignancies further comprising an adjuvant; and the preventing and/or treating agent to use as a cancer vaccine for hematologic malignancies, which allowed prevention and/or treatment of hematologic malignancies such as an HLA-A24 positive hematologic malignancies or the hematologic malignancies that are HLA-A24 positive and express a protein containing the peptide.